Complex Relationships between Occupation, Environment, DNA Adducts, Genetic Polymorphisms and Bladder Cancer in a Case-Control Study Using a Structural Equation Modeling

Stefano Porru1, Sofia Pavanello2*, Angela Carta1, Cecilia Arici1, Claudio Simeone3, Alberto Izzotti4, Giuseppe Mastrangelo2

1 Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, Section of Public Health and Human Sciences, University of Brescia, Brescia, Italy, 2 Department of Cardiac, Thoracic, and Vascular Sciences, Unit of Occupational Medicine, University of Padova, Padova, Italy, 3 Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, Section of Surgical Specialties, University of Brescia, Brescia, Italy, 4 Department of Health Sciences, University of Genoa, Italy/Mutagenesis Unit, IRCCS Hospital-University San Martino Company – IST National Institute for Cancer Research, Genoa, Italy

Abstract

DNA adducts are considered an integrative measure of carcinogen exposure and the initial step of carcinogenesis. Their levels in more accessible peripheral blood lymphocytes (PBLs) mirror that in the bladder tissue. In this study we explore whether the formation of PBL DNA adducts may be associated with bladder cancer (BC) risk, and how this relationship is modulated by genetic polymorphisms, environmental and occupational risk factors for BC. These complex interrelationships, including direct and indirect effects of each variable, were appraised using the structural equation modeling (SEM) analysis. Within the framework of a hospital-based case/control study, study population included 199 BC cases and 213 non-cancer controls, all Caucasian males. Data were collected on lifetime smoking, coffee drinking, dietary habits and lifetime occupation, with particular reference to exposure to aromatic amines (AAs) and polycyclic aromatic hydrocarbons (PAHs). No indirect paths were found, disproving hypothesis on association between PBL DNA adducts and BC risk. DNA adducts were instead positively associated with occupational cumulative exposure to AAs (p = 0.028), whereas XRCC1 Arg 399 (p < 0.006) was related with a decreased adduct levels, but with no impact on BC risk. Previous findings on increased BC risk by packyears (p < 0.001), coffee (p < 0.001), cumulative AAs exposure (p = 0.041) and MnSOD (p = 0.009) and a decreased risk by MPO (p < 0.008) were also confirmed by SEM analysis. Our results for the first time make evident an association between occupational cumulative exposure to AAs with DNA adducts and BC risk, strengthening the central role of AAs in bladder carcinogenesis. However the lack of an association between PBL DNA adducts and BC risk advises that these snapshot measurements are not representative of relevant exposures. This would envisage new scenarios for biomarker discovery and new challenges such as repeated measurements at different critical life stages.

Citation: Porru S, Pavanello S, Carta A, Arici C, Simeone C, et al. (2014) Complex Relationships between Occupation, Environment, DNA Adducts, Genetic Polymorphisms and Bladder Cancer in a Case-Control Study Using a Structural Equation Modeling. PLoS ONE 9(4): e94566. doi:10.1371/journal.pone.0094566

Editor: Courtney G. Montgomery, Oklahoma Medical Research Foundation, United States of America

Received November 13, 2013; Accepted March 17, 2014; Published April 10, 2014

Copyright: © 2014 Porru et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was funded by the Italian Ministry of University and Research and by the University of Brescia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: sofia.pavanello@unipd.it

Introduction

Tobacco smoking and occupational exposures to aromatic amines (AAs) and polycyclic aromatic hydrocarbons (PAHs) are the major risk factors for bladder cancer (BC) [1,2]. Moreover increasing evidence suggests a significant influence of genetic predisposition on BC incidence [3,4].

The formation of reactive metabolites of AAs and PAHs and their binding to DNA to give unrepairable/stable adducts, all modulated by genetic polymorphisms of metabolic and DNA repair enzymes, are considered critical events alongside the theoretical pathway that links exposure to BC [5]. “Bulky” DNA adduct measurement has been therefore considered an integrated marker of both exposure to aromatic compounds and ability to activate carcinogens and repair DNA damage [6,7]. Significantly higher levels of aromatic DNA adducts have been found in the bladder cancer biopsies from smokers [8,9]. Moreover persistent aromatic-DNA adducts causing mutations, including mutational “hot spots” in the bladder P53 gene, has provided a solid mechanistic view on how DNA adducts may drive bladder tumourogenesis [10]. Furthermore, some DNA modifications induced by aromatic compounds in the bladder are found to mirror those in the peripheral blood lymphocytes (PBLs) [11,12]. This has addressed the possibility of measuring such biomarker in accessible tissues which can be easily and non-invasively obtained from humans.

Many factors can however interfere in the theoretical pathway that links carcinogenic exposure to BC, such as multiple exposures (e.g., tobacco smoke, occupational exposure, fruit and vegetables consumption), their characterization (e.g., level, route, reliability)
as well as the modulating role (increasing, protecting or having no effect) possibly played by polymorphic genes involved in metabolism and DNA repair [13]. To the best of our knowledge, only few studies have explored the hypothesis that PBLs DNA adduct levels can be associated to or predictive of BC risk. Results from three retrospective hospital based case-control showed that the risk indicator measuring the association between DNA adducts and BC was higher than 1.0 [14,15], not different from unity [17], or lower than 1.0 [16]. More precisely, DNA adducts were associated to the risk of BC but independently from smoking habits [14,15], while other authors [16] did not find any association between BC risk and bulky DNA adducts in never smokers. In the nested case-control prospective study, DNA adducts were not associated with BC risk [17]; overall, these conflicting results are hard to be explained from the biological viewpoint. Moreover, no study apparently estimated the complex interactions between DNA adducts, multiple genetic polymorphisms, occupational exposure to AAs and PAHs, and BC risk.

We previously assessed the interaction between occupational and environmental exposures with metabolic and DNA-repair polymorphisms on the risk of BC in retrospective hospital based case-control study [18–22].

The aim of this study was twofold: to investigate the extent to which PBL DNA adducts and BC risk were separately affected by genetic polymorphisms, environmental and occupational exposures; and to explore whether the formation of DNA adducts involved an additional increase in BC risk. These complex interrelationships were appraised using the analysis of structural equation modeling (SEM).

Subjects and Methods

Subjects

Study population, collection of data and statistical analysis are described in previous publications [18–22].

Briefly, the design was a hospital-based case-control study. The inclusion criteria were being male, aged between 20 and 80, resident in the Brescia province (Northern Italy). The cases were 201 newly diagnosed, histologically confirmed BC patients, admitted in the Urology Departments of the two main hospitals of Brescia from July 1997 to December 2000. The controls were 214 patients affected by various urological non-neoplastic diseases, frequency matched to cases by age (± 5 years), period and hospital of admission. A written informed consent was obtained from each recruited subject and the study was approved by the the Spedali Civili di Brescia Ethical Committee.

All subjects were administered a questionnaire during hospital admission to collect information on demographic variables and lifetime history of smoking, coffee and other liquid consumption, diet habits, occupations. Occupational exposures to PAHs and AAs were estimated according to methodology described in previous publication [22]. An index of cumulative exposure to AAs and PAHs, separately, was calculated as product (i×f×l) of length (l), intensity (f) and frequency (i) of exposure in each job, summing up as many products as were necessary to take into account all jobs done. Life-long consumption of cigarettes was calculated as packyears. The lifelong time-weighted average of cups/day of coffee was recoded as 0 (never drinkers), ≥3, 4, ≥5 cups/day. PAHs containing food, fruit, large leaf vegetables and other vegetables consumption was divided into four categories (less than once/month; less than once/week; 1–3 times/week; more than 3 times/week).

Genotyping of GSTM1, GSTT1, GSTP1, NAT1, NAT2, SULT1A1, XRCC1-3, XPD, CYP1A2, MPO, COMT, MnSOD and NQO1 was assessed using Amplification Refractory Mutation System assay and using the GeneAmp PCR System 9700 (Applied Biosystems, Italy). PCR were followed by enzymatic digestion and PCR-RFLP analysis, as previously described [18–22].

All variables proved to be associated with BC risk at univariable logistic regression were forced in a multivariable unconditional logistic regression model and then chosen by backwards stepwise selection (with p<0.05 as criterion). BC risk significantly increased with packyears, heavy coffee drinkers, MnSOD (Val/Val genotype), while decreased with large leaf vegetables consumption and MPO (G-463A homozygous variant). Cumulative exposure to AAs was not statistically significant but it was retained because being a substantial confounder [19,22].

DNA extraction from PBLs

Blood samples were collected from all the subjects during hospital admission and on the same day processed by centrifugation for obtaining peripheral blood lymphocytes (PBLs). The protocol for automated DNA extraction was performed according to Extranext kit (Extran BC, by TALENT) following the manufacturer’s instructions as previously described [20]. In particular 2.5 ml of buffy coats prepared from up to 10 ml of whole blood were processed for DNA extractions. A typical yield ranged from 150 to 400 µg DNA/extraction from a normal donor.

32P-Post-labeling analysis of DNA adducts

Aliquots of 5 µg DNA were assayed for the presence of bulky-DNA adducts by 32P-postlabeling after enrichment with Nuclease P1 as previously described [23,24]. Resolution of DNA adducts was performed by multidirectional thin-layer chromatography (TLC), using polyethyleneimine (PEI)-cellulose plates [25]. Briefly, 5 µg DNA were enzymatically digested to 3’-mononucleotides with 0.14 U/µg DNA of micrococcal nuclease and 1 mU/µg DNA of spleen phosphodiesterase for 3–4 hours at 37°C. After the enrichment procedure by Nuclease P1 digestion, DNA bases were labelled with 50 Ci of [gamma-32P]ATP with a specific activity of 5000 Ci per mmol by using 2.5 units of T4 poly nucleotide kinase. 20 µl of postlabeled sample were spotted on the origin of a premarked PEI cellulose sheet and run for the multidirectional TLC chromatography. Following chromatography, TLC sheets were dried and electronic autoradiography performed using a 32P imager (InstanImager, Packard, MD, USA). A benzo(a)-pyrene diolepoxide-N2-dGp reference standard (National Cancer Institute Chemical Carcinogen Reference Standard Repository, Midwest Research Institute, Kansas City, Mo.) was used as a positive control in each labeling experiment. DNA adducts levels were measured as relative adduct level per 109 nucleotides.

Statistical analysis

In fitting SEM, packyears, coffee and vegetable consumption, MnSOD, MPO, cumulative AA exposure (variables associated with BC risk according to previous publications) plus XRCC1 (see below) were used as exogenous variables (corresponding to predictors in regression based techniques). Both BC risk and adducts could be endogenous variables (corresponding to outcome variables), each affected by one or more exogenous variables (hypothesis 1). Alternatively, BC risk could be also influenced indirectly through the formation of DNA adducts (hypothesis 2). The two competing hypotheses were converted in two models of structural equations to find which model fitted best the observed data. SEM structural equations were fitted with “asymptotic distribution free” method because it did not make assumption on joint normality of all the variables and allowed using the variables (particularly adducts, see below) as given. The effect of each
exogenous variable was expressed as standardized (or beta) coefficients that make comparisons easily by ignoring the independent variable’s scale of units. SEM results were both tabulated and presented graphically. We used two SEM’s goodness-of-fit statistics: (1) the chi square test for “model versus saturated” (the saturated model is the model that fits the covariances perfectly); and (2) the stability index obtained from the analysis of simultaneous equation systems.

The sample size required for SEM is dependent on model complexity, the estimation method used, and the distributional characteristics of observed variables [26]. The best option is to consider the model complexity (i.e., the number of exogenous variables) and the following rules of thumb: minimum ratio 5:1 [27,28]; recommended ratio 10:1 [26–29]; recommended ratio 15:1 for data with no normal distribution [29]. With eight exogenous variables used in the SEM model, we should have 120 (≈ 15×8) subjects but they were actually 412 (see below) fulfilling the above requirements.

The analysis was carried out with the statistical package STATA 12.

Results

In the present study, complete individual data were available for 199 (out of 201) cases and 213 (out of 214) controls, totaling 412 (instead of 415) subjects.

Table 1 shows the characteristics of cases and controls. Current and former smoking were more common (chi2 test (2df) = 32.2377; p = 0.000) and coffee intake was higher (Wilcoxon rank-sum test x = -5.756; p = 0.0002) in cases than in controls. No significant differences between cases and controls were found for other demographic variables and putative risk factors of BC.

Table 2 shows that mean, standard deviation, median, inter-quartile range and CV% of adduct levels were similar in cases and controls. Any transformations failed to reduce its skewness (data not shown).

Table 3 shows three groups of SEM results.

1. Structural equations. It can be seen the beta coefficients (with “minus” sign indicating an inverse relationship), standard errors, z tests with p-values, and 95% confidence intervals for each of two structural equation models. The first model shows that cumulative occupational exposure to AAs (beta = 0.117; p = 0.028) is associated with increased DNA adduct levels, whereas XRCCI Arg 399 (beta = -0.129; p<0.006) with decreased levels. We calculated the corresponding study-wise p-value as (1-(1-alpha)^n), where “alpha” was 0.006 and “n” was 6. The result was 0.035464301 (well below the threshold of statistical significance), indicating that the error probability of the second model cannot be an effect of random fluctuations. The second model shows that cigarette smoking (packyears; beta = 0.256; p<0.001), coffee (beta = 0.166; p<0.001), cumulative occupational AAs exposure (beta = 0.084; p=0.041) and MnSOD (beta = 0.119; p=0.009) increased the BC risk whereas MPO (beta = -0.115; p<0.008) decreased it. No indirect paths were demonstrated (disproving hypothesis 2).

2. Variance explained by the above fitting was about 4% for DNA adducts and roughly 14% for the risk of BC.

3. Covariance between the two endogenous variables (BC risk and adducts) was not significant (p = 0.441, last row of table 1). This finding demonstrated that these variables were not correlated to each other and that supported the hypothesis 2; i.e., DNA adducts did not affect BC risk in our population.

The value of chi square test for the discrepancy of the specified model versus saturated model was 0.00 with p-value equal to 1.00. The stability index was 0.00, indicating that SEM satisfies stability condition.

Using the graphical interface of SEM, the results shown in table 3 were displayed as path diagram in figure 1. In this figure, square boxes stand for variables, circles indicate variances, arrows specify the direction of causal flow, an arrowed route is a path, and the estimated beta coefficients appeared along the paths. The effect of one variable on another is called direct. There was no evidence of indirect effect (one variable affecting another variable which in turn affects a third), indicating that bladder cancer risk in our population was not further increased through formation of DNA adducts.

Discussion

DNA adducts as outcome

Since DNA adducts in PBLs are considered an integrative measure of carcinogen exposure, absorption, distribution, metabolism, and DNA repair, they have been referred to as biomarker of ‘biologically effective dose’ i.e. a measure of the amount of the carcinogen at the critical target [13]. Moreover carcinogen DNA adduct levels in more accessible circulating PBLs mirror those in the bladder tissue [11,12], which are considered an initial step in carcinogenesis.

However, in the present study, consistent with other literature findings, bulky DNA adducts detected by the nuclease P1 method of 32P-post-labeling were not associated with an increased BC risk, probably because the adducts measured in PBLs at the time of BC diagnosis represent snapshots that are not necessarily representative of exposures relevant for BC risk that occurred in the past.

Adduct levels were instead associated with XRCCI399Arg carriers who presented a significant reduction in DNA adducts level, but with no effect on the risk of BC. Our results agree with previous studies reporting XRCCI399Arg associated with lower levels of bulky DNA adducts [30,31], due to higher DNA repair activity [32], and with two recent meta-analyses where XRCCI Arg399Gln polymorphism was not related to BC risk [33,34].

In the present study, likewise the above reported studies [14,15,17], no relationship between DNA adduct levels and smoking was reported. Previous 32P-post-labeling studies have reported inconsistent results on the association between the adduct levels in PBLs and tobacco smoking [35–39]. Discrepancies may depend on the marked interindividual variation in the metabolism of smoking carcinogens, which results in different DNA adduct levels for similar degrees of exposure [40]. Moreover, most of studies on the effect of smoking on PBLs bulky-DNA adduct levels did not reveal any significant differences [35,36,39], suggesting that adducts in PBLs from smokers may result from sources other than tobacco smoking.

We also found an association between cumulative occupational exposure to AAs and PBL adduct levels that was instead not reported by other authors most probably because information about occupational exposures was too limited to allow evaluation, even in the largest case-control study nested in EPIC cohort [17].

BC risk as outcome

We confirmed by SEM analysis the biological plausible protective effect of MPO A/A [21], and the risk effect of MnSOD.
Val/Val on BC [21,41]. The genetic polymorphism of enzymes involved in individual response to oxidative stress is likely involved in modulating the individual response to environmental exposures such as tobacco smoking, coffee drinks and AAs exposure [21]. In this study we also confirmed our previous results on the association between smoking habit and coffee drinking on BC risk, where the latter might be attributed to residual confounding by inadequate adjustment for cigarette smoking (which is over-represented among those who drink the most coffee/caffeine) [22]. As shown in table 3, the level of statistical significance of beta coefficients was particularly high for the association between BC risk and, on the other hand, packyears (beta = 0.256; p<0.001) and coffee (beta = 0.166; p<0.001); as well as for the association between decreased DNA adduct and XRCC1 Arg 399 (beta = −0.129; p<0.006). Despite this, the proportion to which SEM fitting accounts for the dispersion of data (variance explained) was as low as 16% for BC risk, and 4% for DNA adducts. Therefore most variation of outcomes should be attributed to unknown predictors.

With regard to the relationship of occupational exposures to AAs and PAHs, DNA adducts and BC risk the literature is scanty and those few published studies have only found an exposure-independent association between adducts and BC risk. Our study precisely evaluated the occupational exposure history to AAs and PAHs, and noted a significant correlation between occupational exposure to AAs and BC, and adduct levels too. Therefore occupational exposure to AAs is confirmed as central risk factor for BC development. Finally the present work was carried out in the context of a biologically plausible and hypothesis-driven study design consistent with the available literature data.

Table 1. Distribution of demographic characteristics, life habits, and occupational exposures in cases and controls.

| Age     | Cases (n = 199) | Controls (n = 213) |
|---------|----------------|--------------------|
|         | Number (Percentage) | Number (Percentage) |
| ≤45     | 14 (7)          | 19 (9)             |
| 46–55   | 25 (13)         | 28 (13)            |
| 56–65   | 58 (29)         | 76 (36)            |
| 66–75   | 82 (41)         | 69 (32)            |
| ≥75     | 20 (10)         | 21 (10)            |

Education

| Level  | Cases (n = 199) | Controls (n = 213) |
|--------|----------------|--------------------|
| 0–5    | 106 (54)       | 111 (53)           |
| 6–8    | 60 (30)        | 47 (22)            |
| 9–13   | 25 (13)        | 41 (20)            |
| ≥14    | 7 (4)          | 11 (5)             |

Lifetime smoking

| Level  | Cases (n = 199) | Controls (n = 213) |
|--------|----------------|--------------------|
| Never  | 17 (9)         | 54 (25)            |
| Light (≤26 packyears) | 56 (28)   | 78 (37) |
| Heavy (>26 packyears) | 126 (63) | 81 (38) |

Occupational cumulative exposure to PAHs

| Level  | Cases (n = 199) | Controls (n = 213) |
|--------|----------------|--------------------|
| Never  | 128 (64)       | 143 (67)           |
| Ever   | 71 (36)        | 70 (33)            |

Occupational cumulative exposure to AAs

| Level  | Cases (n = 199) | Controls (n = 213) |
|--------|----------------|--------------------|
| Never  | 182 (91)       | 203 (95)           |
| Ever   | 17 (9)         | 10 (5)             |

Coffee consumption (cups/day)

| Level  | Cases (n = 199) | Controls (n = 213) |
|--------|----------------|--------------------|
| Mean   | 2.33 (±2.30)   | 1.58 (±1.62)       |
| 5th–95th percentiles | 0–8          | 0–6               |

doi:10.1371/journal.pone.0094566.t001

Table 2. Summary statistics (mean, standard deviation, median, interquartile range, number of subjects) for “ln_adducts” in cases, controls, and total population.

|         | Mean   | Std. Dev. | CV% | Median | Inter quartile range | N  |
|---------|--------|-----------|-----|--------|----------------------|----|
| Cases   | 0.82   | 1.20      | 146 | 0.57   | 2.00                 | 185|
| Controls| 0.77   | 1.09      | 142 | 0.46   | 1.73                 | 180|
| Total   | 0.80   | 1.14      | 143 | 0.51   | 1.83                 | 365|

doi:10.1371/journal.pone.0094566.t002
Table 3. SEM results: beta coefficients (with “minus” sign indicating inverse relationship), standard errors, z tests and the corresponding p-values, along with 95% confidence intervals for endogenous variables of structural equations; variances and covariance.

| Endogenous variable | Exogenous variables | Beta Coef. | Std. Err. | z  | P>|z| | 95% CI Lower | 95% CI Upper |
|---------------------|---------------------|------------|-----------|----|-------|----------------|----------------|
| Structural Equations| Adducts             | Packyears  | 0.064     | 0.048 | 1.35 | 0.177          | -0.029         | 0.157         |
|                     |                     | Coffee     | 0.015     | 0.047 | 0.31 | 0.757          | -0.078         | 0.107         |
|                     |                     | Occupational exposure to AAs | 0.117 | 0.048 | 2.46 | 0.014          | 0.024          | 0.210         |
|                     |                     | XRCC1      | -0.129    | 0.047 | -2.75 | 0.006         | -0.221         | -0.037        |
|                     |                     | MPO        | -0.024    | 0.039 | -0.63 | 0.531          | -0.100         | 0.052         |
|                     |                     | MnSOD      | -0.053    | 0.045 | -1.17 | 0.244         | -0.142         | 0.036         |
| Cancer Risk         | Packyears           | 0.256      | 0.041     | 6.19  | 0.000 | 0.175         | 0.337         |
|                     |                     | Coffee     | 0.166     | 0.043 | 3.83  | 0.000         | 0.081         | 0.250         |
|                     |                     | AA         | 0.084     | 0.034 | 2.45  | 0.014         | 0.017         | 0.152         |
|                     |                     | XRCC1      | -0.028    | 0.044 | -0.65 | 0.519         | -0.114         | 0.058         |
|                     |                     | MPO        | -0.115    | 0.036 | -3.21 | 0.001         | -0.185         | -0.045        |
|                     |                     | MnSOD      | 0.120     | 0.044 | 2.71  | 0.007         | 0.033         | 0.206         |
| Variances           | Adducts             | 0.962      | 0.018     |       |       | 0.927         | 0.998         |
|                     | Cancer Risk         | 0.858      | 0.025     |       |       | 0.811         | 0.908         |
| Covariance          | Adducts × Cancer Risk | -0.038   | 0.047     | -0.80 | 0.421 | -0.131         | 0.055         |

Packyears = Life-long consumption of cigarettes.
Coffee = Life-long time-weighted average of cups/day of coffee.
AA = Occupational cumulative exposure to aromatic amines.
XRCC1 = X-ray repair cross-complementing protein 1.
MPO = Myeloperoxidase (G-463A homozygous variant).
MnSOD = Manganese Superoxide Dismutase (Val/Val genotype).
doi:10.1371/journal.pone.0094566.t003
DNA Adducts on Bladder Cancer Risk by SEM Analysis

In addition, the correlation we found between AAs exposure and BC risk is biologically plausible, because AAs are activated in liver and transported by blood proteins to the bladder where, under acidic conditions [42,43] or, enzymatically by O-acetylation of N-hydroxy arylamine (predominantly by the N-acetyltransferase 1 [NAT1] isozyme), are further activated to the ultimate carcinogen [44]. This result also suggests that occupational exposure history collected by questionnaire through interview could be a reliable measurement of exposures to AAs in such studies.

Unlike AAs, cumulative exposure to PAHs was not associated with BC risk. Experimental evidence suggests that PAHs are slowly absorbed through most tissues. For instance, in the case of dermal exposure, considered the main route in the industry [15], absorption accounts for a small fraction of applied dose, and PAHs are enzymatically activated and degraded at this site of entry [46–48]. The concentration and persistence of PAHs in the lung is largely related with inhalation of PAHs containing dust [49,50]. The high propensity of PAHs to act as carcinogens at the sites of entry is supported by several experimental studies [51].

DNA adducts and BC risk

The results of literature on the association between DNA adducts and risk of BC are scanty and not consistent. A strong correlation between and the risk of BC and PBLs DNA adducts (nuclease P1 and 32P-postlabeling) were not associated with the subsequent bladder cancer insurgence in a prospective nested case-control study [17]. The findings of this latter study are probably more reliable and meaningful than those of earlier investigations [14,15], because DNA adducts were measured years before the onset of disease, thus ruling out the possibility that the higher adduct levels were due to a condition associated with an already existing cancer.

We did not find any relation between DNA adducts and BC risk. However, we cannot exclude such relationship. In fact, a limitation of the present study is that adducts measured by nuclease P1 method of 32P-postlabeling are non-specific because the responsible electrophilic substance cannot be identified. Moreover, DNA adducts measure at time of diagnosis may be not representative of cumulative doses of carcinogens that may cause cancer. Environmental and occupational exposures vary both qualitatively and quantitatively over time due to changes in lifestyle, place of residence, employment, etc., and the impact of a given exposure on the risk of cancer cannot be constant throughout the life of an individual [13]. This fact, combined with the awareness that the rate and speed of repair of various DNA adducts are different and their permanence mainly depends from life span of PBLs, from a few days to a few weeks, poses uncertainty on the significance of such short-term exposure biomarker in relation to the risk of cancer. Given the long latency of carcinogen-related malignancies – that is the time between the beginning of exposure and the onset of disease – the retrospective assessment of carcinogen exposures, especially via biomarkers, represents a challenge for both epidemiology and clinical medicine.

Perspectives (including SEM analysis)

New opportunities for biomonitoring of carcinogens may derive from measuring exposures from all sources both external and internal that occur throughout the lifespan. This approach named exposome by Wild [52] is represented by the set of chemicals derived from sources outside genetic control that include diet, pathogens, microbiome, smoking, psychological stress, drugs and pollution [53]. Indeed, these new technologies are opening new scenarios for biomarker discovery but new challenges as well, that include the need of repeated measurements of global sets of biomarkers to be collected at different critical life stages. Only in this way can the dynamics of exposures and early and late effects be captured.

In medicine and natural sciences a given outcome is often affected or influenced by more than one thing simultaneously. Multivariate techniques try to statistically account for these differences, adjusting an outcome measure Y to a 1 unit change in X, holding all other variables constant. However, it may be that other variables are not likely to remain constant: a change in X can produce a change in Z (direct effect) which in turn produces a change in Y (indirect effect). Both the direct and indirect effects of X on Y must be considered if we want to know what effect a change in X will have on Y. This can be done mathematically and statistically only using SEM. The procedure decomposes a correlation between two variables into its component parts: direct effects, indirect effects, common causes (X affects both Y and Z; this is spurious association) and correlated causes (X is a cause of Z and X is correlated with Y). The user is required to state, often using a path diagram, the way that he/she believes the variables are inter-related. Via some complex internal rules, SEM decides which model fits data better. This method is more suitable to analyze complex interrelationships because it tests causal relationships rather than mere correlations.
In our opinion, the statistical analysis with SEM is one strength of the present research. Other strengths of the study are the thorough and reliable collection of several personal, occupational and environmental variables, the multiple genetic polymorphisms and endpoints, the significant number of subjects, as compared to other similar studies, the adduct analysis [14–17], the quality of DNA adduct analysis, the sample size required for calculation of SEM; here, the actual number of 412 cases was much higher than the maximum required sample size of 120 subjects estimated according to different assumptions (see above: statistical analysis).

Conclusions

Using the SEM analysis, a statistical technique that combines observed data and qualitative causal assumptions and tests whether and how variables are interrelated through a system of equations, we found that PBL DNA adducts was not associated with BC risk. This suggests that this measure at time of diagnosis may not be representative of dose of carcinogens that may cause cancer. However the new finding stemming from this study sustains that occupational cumulative exposure to AAs were associated with both DNA adducts and with BC risk. This agrees with the propensity of AAs to act as carcinogens away of the sites of entry after being transported by blood proteins to the bladder and confirm exposure to AAs, determined by blood DNA adduct, as central risk factor for BC development. Moreover XRCCL139 Arg polymorphism has a role in repairing PBL DNA adducts but no impact on individual susceptibility to BC. Previous findings on the influence of smoking, coffee intake, MPO A/A and MsdOD Val/Val polymorphisms on BC risk were also confirmed by SEM analysis. A direct effect of these predictor variables was observed on each outcome variable. Our study envisages new scenarios, entailing the need of repeated DNA adduct measurements at different critical life stages and proper analytical techniques, for example during occupational exposure to AAs, as well as the appraisal of the complex relationship between gene and environment, by means of SEM analysis.

Author Contributions

Conceived and designed the experiments: SP SP GM. Performed the experiments: SP AC SA SI CM. Analyzed the data: SP AC SA SI CM. Contributed reagents/materials/analysis tools: SP AC SA SI CM. Wrote the paper: SP AC SA SI CM.

References

1. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C (2006) Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol 3: 327–340.
2. Bosetti C, Boffetta P, La Vecchia C (2007) Occupational exposures to polycyclic aromatic hydrocarbons, and respiratory and urinary tract cancers: a quantitative review to 2005. Ann Oncol 18: 431–446.
3. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, et al. (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63: 234–241.
4. Chu H, Wang M, Zhang Z (2013) Bladder cancer epidemiology and genetic susceptibility. J Biomed Res 27: 170–178.
5. Pfeifer GP, Deniseno MF, Olivier M, Tretjakova N, Hecht SS, et al. (2002) Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancer. Oncogene 21: 7435–7451.
6. Pavanello S, Palloru A, Clomero E (2008) Influence of GSTM1 null and low repair XPC PAT+ on anti-B[a]PDE-DNA adduct in mononuclear white blood cells of subjects low exposed to PAHs through smoking and diet. Mutat Res 630: 195–204.
7. Loeb LA, Harris CC (2008) Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res 68: 6893–6872.
8. Talaska G, Al-Jubier AZSS, Kadilahar FF (1991) Smoking related carcinogen-DNA adducts in biopsy samples of human urinary bladder: identification of N-(deoxyguanosin-8-yl)-4-aminobiphenyl as a major adduct. Proc Natl Acad Sci USA 88: 5350–5354.
9. Talaska G, Schamer M, Casetta G, Tizzani A, Vineis P (1994) Carcinogen-DNA adducts in bladder biopsies and urothelial cells: a risk assessment exercise. Cancer Lett 84: 93–97.
10. Yoon JI, Kim SI, Tommasi S, Besaratinia A (2012) Organ specificity of the bladder carcinogen 4-aminobiphenyl in inducing DNA damage and mutation in mice. Cancer Prev Res (Phila) 5: 299–308.
11. Zhou Q, Talaska G, Jaeger M, Haefke S, et al. (2004) Benzidine-DNA adduct levels in human peripheral white blood cells significantly correlate with levels in exfoliated urothelial cells. Mutat Res 558: 241–244.
12. Airoldi L, Orsi F, Magagnotti C, Coda R, Randone D, et al. (2002) Determinants of 4-aminobiphenyl-DNA adducts in bladder cancer biopsies. Carcinogenesis 23: 861–866.
13. Wild CP (2009) Environmental exposure measurement in cancer epidemiology. Mutat Res 672: 117–129.
14. Peluso M, Airoldi L, Armelone M, Martone T, Coda R, et al. (1998) White blood cell DNA adducts, smoking, and NAT2 and GSTM1 genotypes in bladder cancer: a case-control study. Cancer Epidemiol Biomarkers Prev 7: 341–346.
15. Peluso M, Airoldi L, Magagnotti C, Fiorini L, Munnia A, et al. (2000) White blood cell DNA adducts and fruit and vegetable consumption in bladder cancer. Carcinogenesis 21: 183–187.
16. Castaño-Valenzuela G, Talaska G, Rothman N, Algardh J, Garcia-Closas M, et al. (2007) Bulky DNA adduct formation and risk of bladder cancer. Cancer Epidemiol Biomarkers Prev 16: 2155–2159.
17. Peluso M, Munnia A, Hock G, Krzyzanowski M, Vlegga F, et al. (2005) DNA adducts and lung cancer risk: a prospective study. Cancer Res 65: 1042–1048.
18. Crotwell L, Piacentini D, Gelati U, Carta A, Scotto Di Carlo A, et al. (2000) Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCCL1, XRCCL3, XPD genetic polymorphisms and coffee consumption: a case-control study. Eur J Epidemiol 23: 355–362.
19. Hung RJ, Boffetta P, Brennan P, Malaveille C, Hautefeuille A, et al. (2004) GST, NAT, SULT1A1, CYPIB1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 110: 598–604.
20. Shen M, Hung RJ, Brennan P, Malaveille C, Donato F, et al. (2003) Polymorphisms of the DNA repair genes XRCCL1, XRCCL3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. Cancer Epidemiol Biomarkers Prev 12: 1239–1240.
21. Hung RJ, Boffetta P, Brennan P, Malaveille C, Gelati U, et al. (2004) Genetic polymorphisms of MPO, COMT, MsdOD, NQO1, interactions with environmental exposures and bladder cancer risk. Carcinogenesis 25: 973–978.
22. Pavanello S, Mastrandego G, Paciotti D, Campagna M, Palloru A, et al. (2010) CYPIA2 polymorphisms, occupational and environmental exposures and risk of bladder cancer. Eur J Epidemiol 25: 491–500.
23. Pavanello S, Meis AG (1994) Human peripheral blood lymphocytes as a cell model to evaluate the genotoxic effect of coal tar treatment. Environ Health Perspect 102 Suppl 9: 95–99.
24. Izozgi A (1998) Detection of modified DNA nucleotides by postlabelling procedures. Toxicology Methods 8:175–205.
25. Gupta RC, Reddy MV, Randarth K (1982) 3D postlabeling analysis of non-radioactive aromatic carcinogens—DNA adducts. Carcinogenesis 3: 1081–1092.
26. Kline R (2005) Principles and Practice of Structural Equation Modeling (2nd ed.). New York: The Guilford Press.
27. Bentler P, Chou C (1987) Practical issues in structural modeling. Sociological Methods and Research 16: 78–117.
28. Worthington R, Whittaker T (2006) Scale Development Research. A Content Analysis and Recommendations for Best Practices. The Counseling Psychologist 34: 806–838.
29. Hair J, Black W, Babin B, Anderson R, Tatham R (2006) Multivariate Data Analysis (6th ed.). New Jersey: Pearson Educational, Inc.
30. Matullo G, Palli D, Peluso M, Guarnera S, Cartron S, et al. (2001) XRCCL1, XRCCL3, XPD gene polymorphisms, smoking and (32P)-DNA adducts in a sample of healthy subjects. Carcinogenesis 22: 1437–1445.
31. Ji G, Gu A, Zhou Y, Shi X, Xia Y, et al. (2010) Interactions between exposure to environmental polycyclic aromatic hydrocarbons and DNA repair gene polymorphisms on bulky DNA adducts in human sperm. PLoS One 5(10): e13115.
32. Lunn RM, Langlois RG, Hsieh LL, Thompson CL, Bell DA (1999) XRCCL1 polymorphisms: effects on allotax B1-DNA adducts and glycophorin A variant frequency. Cancer Res 59: 2537–2541.
33. Fang Z, Chen F, Wang X, Yi S, Chen W, et al. (2013) XRCCL1 Arg194Trp and Arg280His polymorphisms increase bladder cancer risk in Asian population: evidence from a meta-analysis. PLoS One 8(3): e64801.
34. Zhao W, Zhang L, Cai L, Zhu B, Chen Z (2013) XRCCL1 Arg99Gln polymorphism and bladder cancer risk: updated meta-analyses based on 5767 cases and 6919 controls. Exp Biol Med (Maywood) 238: 66–76.
35. Phillips DH, Scholer B, Hower A, Bailey E, Kostie S, et al. (1998) Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int J Cancer 46: 569–575.
36. Phillips DH, Hower A, Grover PL (1998) Aromatic DNA adducts in human bone marrow and peripheral blood leukocytes. Carcinogenesis 7: 2071–2075.
37. Jahnke GA, Thompson CL, Walker MP, Gallagher JE, Lucier GW, et al. (1990) Multiple DNA adducts in lymphocytes of smokers and nonsmokers determined by 32-P-postlabelling analysis. Carcinogenesis 11: 205–211.
38. Savela K, Hemminki K (1991) DNA adducts in lymphocytes and granulocytes of smokers and nonsmokers detected by the 32-P-postlabelling assay. Carcinogenesis 12: 503–508.
39. Van Maanen JMS, Maas LM, Hageman G, Kleinjans JCS, Van Agen B (1994) DNA adduct and mutation analysis in white blood cells of smokers and nonsmokers. Environ Mol Mutagen 24: 46–50.
40. Perera FP (1996) Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention. J Natl Cancer Inst 88: 496–507.
41. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, et al. (2003) The Ala16Val genetic polymorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13: 145–157.
42. Kadlubar FF (1991) Carcinogenic aromatic amine metabolism and DNA adduct detection in human. In: Emster L, editor. Xenobiotics and cancer. London: Taylor & Francis, Ltd. pp. 329–338.
43. Bartsch H, Malaveille C, Friesen M, Kadlubar FF, Vineis P (1993) Black (air-cured) and blond (flue-cured) tobacco cancer risk. IV. Molecular dosimetry-studies implicates aromatic amines as bladder carcinogens. Eur J Cancer 29: 1199–1207.
44. Frederickson SM, Messing EM, Renikoff CA, Swaminathan S (1994) Relationship between in vivo acetyltransferase phenotypes and cytosolic N-acetyltransferase and O-acetyltransferase activities in human uroepithelial cells. Cancer Epidemiol Biomark Prev 3: 25–32.
45. Jongeneelen FJ (1992) Biological exposure limit for occupational exposure to coal tar pitch volatiles at cokeovens. Int Arch Occup Environ Health 63: 511–516.
46. Kao J, Patterson FK, Hall J (1985) Skin penetration and metabolism of topically applied chemicals in six mammalian species, including man: an in vitro study with benzo[a]pyrene and testosterone. Toxicol Appl Pharmacol 81: 502–516.
47. Ng KM, Chu I, Bronaugh RL, Franklin CA, Somers DA (1992) Percutaneous absorption and metabolism of pyrene, benzo[a]pyrene, and di(2-ethylhexyl)phthalate: comparison of in vitro and in vivo results in the hairless guinea pig. Toxicol Appl Pharmacol 115: 216–223.
48. VanRooij JG, De Roos JH, Bodelier-Bade MM, Jongeneelen FJ (1993) Absorption of polycyclic aromatic hydrocarbons through human skin: differences between anatomical sites and individuals. J Toxicol Environ Health 38: 355–368.
49. Albert RE, Miller ML, Cody T, Andringa A, Shukla R, et al. (1991) Benzo[a]pyrene-induced skin damage and tumor promotion in the mouse. Carcinogenesis 12: 1273–1280.
50. Wolterbeek AP, Schoevers EJ, Rutten AA, Feron VJ (1995) A critical appraisal of intratracheal instillation of benzo[a]pyrene to Syrian golden hamsters as a model in respiratory tract carcinogenesis. Cancer Lett 89: 107–116.
51. IARC (2010) IARC monographs on the evaluation of carcinogenic risks to humans. Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. Volume 92. International Agency for Research on Cancer, Lyon, France.
52. Wild CP (2012) The exposome: from concept to utility. Int J Epidemiol 41: 24–32.
53. Rappaport SM (2012) Biomarkers intersect with the exposome. Biomarkers 17(6): 483–9.